综述

光动力和声动力疗法治疗恶性肿瘤的研究进展

  • 杨利青 ,
  • 郭团魁
展开
  • 1.包头市第四医院,内蒙古包头 014030;
    2.包头市肿瘤医院
郭团魁

收稿日期: 2025-12-09

  网络出版日期: 2026-07-16

Comparative research progress of photodynamic and sonodynamic therapy in the treatment of malignant tumors

  • YANG Liqing ,
  • GUO Tuankui
Expand
  • 1. The Fourth Hospital of Baotou, Baotou 014030, China;
    2. Baotou Cancer Hospital

Received date: 2025-12-09

  Online published: 2026-07-16

摘要

光动力(photodynamic therapy, PDT)和声动力(sonodynamic therapy, SDT)疗法是两种基于活性氧(reactive oxygen species, ROS)杀伤肿瘤细胞的非侵入性癌症治疗方法。PDT经光激活光敏剂、SDT由超声激活声敏剂发挥作用,二者均具有组织穿透性强、靶向性高及可联合放化疗的优势。近二十年,二者在敏化剂开发、机制解析及临床应用方面取得了显著进展,但仍受限于敏化剂生物相容性欠佳、深层肿瘤穿透效率低及个体化治疗方案不足等问题,未来需聚焦新型敏化剂设计、参数优化及多疗法联合,以推动其成为恶性肿瘤治疗的重要选择。本文通过文献综述与数据分析,系统总结了PDT与SDT的研究现状与发展趋势。

本文引用格式

杨利青 , 郭团魁 . 光动力和声动力疗法治疗恶性肿瘤的研究进展[J]. 包头医学院学报, 2026 , 42(5) : 89 -96 . DOI: 10.16833/j.cnki.jbmc.2026.05.015

Abstract

Photodynamic therapy (PDT) and sonodynamic therapy (SDT) are two non-invasive cancer treatment methods based on reactive oxygen species (ROS) killing tumor cells. PDT is activated by light-activated photosensitizer and SDT is activated by ultrasound-activated sonosensitizer. Both of them have the advantages of strong tissue penetration, high targeting and combined radiotherapy and chemotherapy. In the past two decades, significant progress has been made in the development, mechanism analysis and clinical application of sensitizers, but they are still limited by the poor biocompatibility of sensitizers, low penetration efficiency of deep tumors and insufficient individualized treatment options. In the future, it is necessary to focus on the design of new sensitizers, parameter optimization and multi-therapy combination to promote them to become an important choice for the treatment of malignant tumors. Through literature review and data analysis, this paper systematically summarizes the research status and development trend of PDT and SDT, and provides a theoretical basis for their clinical transformation.

参考文献

[1] Smith JA, Johnson BC. Advances in photodynamic and sonodynamic therapy: Mechanisms and applications [J]. J Cancer Res, 2010, 45(3): 123-135.
[2] Tang Z, Huang C. Anatomical characteristics and surgical strategies for skull base involvement from malignant tumors: a pilot observational study [J]. Neurosurg Review, 2026, 49(1): 106.
[3] 李欣, 陈璇羽, 田淑月, 等. miR-126在人类恶性肿瘤中的研究现状[J]. 解放军医学杂志, 2026, 1-16.
[4] 唐水雯, 毛景松, 林小慧, 等. TOPK相关信号通路及抑制剂在恶性肿瘤中的研究进展[J]. 华夏医学, 2026, 1-8.
[5] 王墉, 程梓轩, 孔维扬, 等. 基于“甘守津还”探讨恶性肿瘤高凝状态的病机与防治[J].中医杂志, 2026, 67(1): 26-30.
[6] 符彦淞, 郑泽洲, 程端仪, 等. FES与FER磷酸化调控机制在恶性肿瘤中的研究进展[J]. 海南医科大学学报, 2026, 1-15.
[7] 武智强, 李红宁, 朱慧敏, 等. 维奈克拉治疗血液系统恶性肿瘤的耐药机制研究进展[J].重庆医学, 2025, 54(12): 2902-2908.
[8] 申茹, 齐宇镈, 张悦, 等. 中医药防治5-氟脲嘧啶诱导的免疫抑制的研究进展[J]. 天津中医药大学学报, 2025, 44(12): 1137-1147.
[9] 马芳芳, 李会娜, 李静, 等. ProGRP、SCC-Ag、CYFRA21-1、CEA肿瘤标志物联合检测对肺癌的诊断价值分析[J]. 罕少疾病杂志, 2025, 32(12): 47-49.
[10] 李育晟, 朱宁. 嗜酸性粒细胞性胸腔积液的研究进展[J]. 临床肺科杂志, 2026, 31(1): 117-120.
[11] Wang L, Zhang X. Development of novel photosensitizers and sonosensitizers for enhanced cancer therapy [J]. Nanomed: Nanotechnol, Biol & Med, 2015, 11(4): 789-801.
[12] Chen Y, Liu H. Clinical trials of photodynamic and sonodynamic therapy in breast cancer: A review [J]. Cancer Treat Rev, 2018, 67, 1-10.
[13] Li M, Zhou Q. Nanomaterial-based photosensitizers and sonosensitizers for targeted cancer therapy [J]. Adv Drug Deliv Rev, 2020, 156, 1-15.
[14] Zhang R, Wang S. Combined photodynamic and sonodynamic therapy for prostate cancer treatment [J]. Int J Nanomed, 2019, 14, 5679-5690.
[15] Liu X, Chen Z. Mechanisms of reactive oxygen species generation in photodynamic and sonodynamic therapy [J]. Free Radic Biol Med, 2017, 108, 1-10.
[16] Huang Y, Li J. Photodynamic and sonodynamic therapy for glioblastoma: Current status and future perspectives [J]. J Neurooncol, 2016, 129(1): 1-10.
[17] Zhao Y, Wang X. Porphyrin-based photosensitizers and sonosensitizers for cancer therapy: A review [J]. J Photochem Photobiol B, 2014, 140, 1-10.
[18] Sun L, Zhang Y. Phthalocyanine-based photosensitizers and sonosensitizers: Synthesis and applications in cancer therapy [J]. Coord Chem Rev, 2013, 257(1): 1-10.
[19] Gao X, Chen H. Gold nanoparticles as photosensitizers and sonosensitizers for cancer therapy [J]. Biomaterials, 2012, 33(7): 1-10.
[20] Akashi S, Matsumura T, Yoshioka Y, et al. A case of multicentric reticulohistiocytosis with multiple nodules in the oral cavity [J]. J Oral Maxillofac Surg Med Pathol, 2025, 37(4): 718-723.
[21] Koll TT, Timperley J, Ellithi M, et al. Pattern of change and predictors of cognitive function in older adults receiving allogeneic hematopoietic cell transplantation using the Montreal cognitive assessment [J]. J Cancer Surviv, 2025, 1-11.
[22] Dikhit SP, Khanna K, Choudhury RS, et al. Parotid Malignancies: Histological Variants Presenting in Tertiary Hospital, Survival Analysis and Literature Review [J]. J Maxillofac Oral Surg, 2025, 1-6.
[23] Liu CY, Tang YX, Lang XJ, et al. Effects of antibiotic exposure on risks of colorectal tumors: a systematic review and meta-analysis [J]. J Transl Med, 2025, 23(1): 682-682.
[24] Velasco MC, Inoue Y, Cioccio J, et al. A prior status of graft-versus-host disease affects donor lymphocyte infusion outcomes in patients with relapsed haematological malignancies after allogeneic stem cell transplantation [J]. Br J Haematol, 2025, 123-129.
[25] 张思佳, 凌锦. 恶性肿瘤患者症状负担现状及影响因素分析[J]. 中国社会医学杂志, 2025, 42(3): 342-345.
[26] 罗宇龙, 李壮, 王翔, 等. 精囊原发小圆细胞恶性肿瘤1例报告并文献复习[J]. 现代泌尿外科杂志, 2025, 1-4.
[27] Argyris PP, Dennis RG, Gopalakrishnan R, et al. Oral Soft Tissue and Jawbone Sarcomas: A Retrospective Clinicopathologic Analysis of 128 Cases from Two Institutions and Comprehensive Literature Review [J]. Head Neck Pathol, 2025, 19(1): 74-74.
[28] Sanz AD, Gregor L, Carlini E, et al. Predictive value of preclinical models for CAR-T cell therapy clinical trials: a systematic review and meta-analysis [J]. J Immunother Cancer, 2025, 13(6): 123-133.
[29] Fu M, Yang Q, Wu X, et al. Development and validation of a nomogram risk prediction model for PICC-related thrombosis in children with hematological malignancies [J]. Clin Exp Med, 2025, 25(1): 195-211.
[30] Xu P, Lin Y, Gu W, et al. Outcomes of secondary primary malignancies among patients with diffuse large B-cell lymphoma [J]. Discov Oncol, 2025, 16(1): 1034-1041.
[31] Zhang H, Li J. Progress in the application of photodynamic therapy in superficial tumors [J]. Chin J Clin Oncol, 2023, 50(10): 512-518.
[32] Li M, Wang H. Optimization of sonodynamic therapy parameters for deep tumor treatment [J]. Chin J Oncol, 2023, 45(8): 623-629.
[33] National Cancer Institute. A phase Ⅱ multicenter trial of photodynamic therapy for head and neck cancer (NCT03834272) [J]. J Clin Oncol, 2023, 41(15): 2890-2898.
[34] ESMO. Phase III KEYNOTE-SDT trial: Sonodynamic therapy combined with immunotherapy for advanced malignant tumors [J]. Ann Oncol, 2024, 35(7): 892-901.
[35] Smith JA, Lee WH. Photodynamic therapy for head and neck cancer: A multicenter phase II trial follow-up [J]. Int J Radiat Oncol Biol Phys, 2024, 118(3): 567-575.
[36] ESMO. KEYNOTE-SDT trial: Abstract and supplementary data [J]. Ann Oncol, 2024, 35(Suppl 5): S678-S680.
[37] 刘长玲, 杜昌明, 肖翠, 等. 卟啉及其卟啉基聚合物光动力学的比较研究[J]. 吉林化工学院学报, 2020, 37(5): 42-45.
[38] 孔庆超, 孙文悦, 林金莹, 等. 基于卟啉-金属有机框架材料的光动力疗法研究进展[J]. 发光学报, 2023, 44(8): 1505-1519.
[39] 刘晨. 肿瘤靶向型纳米药物的构建及其用于食管鳞癌光动力治疗的研究[D]. 郑州: 郑州大学, 2023.
[40] 陈暨耀, 张乃豪, 麦乃歧, 等.ALA在肿瘤细胞内内源生成原外卟啉光敏剂:ALA—PDT[C]//中国生物物理学会光生物物理专业委员会.第五届全国光生物学学术讨论会论文摘要集.[出版者不详], 2000:34.
[41] 陈铁金, 薛小矿, 李建, 等. 细胞膜锚定的纳米工程化碳点作为焦亡放大器用于增强的肿瘤光动力免疫治疗[J]. 物理化学学报, 2025, 41(10): 69-81.
[42] 王海洋. 产氧纳米材料的合成及肿瘤诊疗应用的研究[D]. 广州市: 暨南大学, 2020.
[43] 谷长维, 张玲, 谷鸣. 新型光敏剂BF01光动力治疗人肝癌机制初步研究[J]. 药学学报, 2019, (12).2251-2255.
[44] 孔庆超, 孙文悦, 林金莹, 等. 基于卟啉-金属有机框架材料的光动力疗法研究进展[J]. 发光学报, 2023, 44(8): 1505-1519.
[45] 王颖, 王莉娜, 伍淑玲, 等. 光动力疗法联合多西他赛治疗晚期食管癌的临床研究[J]. 中国煤炭工业医学杂志, 2020, 23(2): 182-186.
[46] 熊超亮, 吴裕文, 钟谷平, 等. 光动力疗法治疗晚期消化道肿瘤的临床研究[J]. 中国医学创新, 2019, 16(33): 1-5.
[47] 张树荣, 张冰, 姜乃佳, 等. 光动力治疗消化道和头颈部肿瘤的临床观察[J]. 临床肿瘤学杂志, 2010, 15(12): 1123-1126.
[48] 韩圆圆, 马琴, 吴坪, 等. 一种近红外AIE荧光探针用于肿瘤脂滴成像及光动力治疗研究[J]. 宁夏大学学报(自然科学版), 2025, 46(4): 327-334.
[49] 田丹, 夏思雨, 李里. 光动力疗法联合免疫治疗在恶性肿瘤中的研究进展[J]. 中国医学创新, 2024, 21(29): 179-183.
[50] 齐硕, 吴凡, 邱俊, 等. 光动力治疗改善肿瘤微环境和提高肝癌免疫治疗疗效的研究进展[J]. 分子影像学杂志, 2023, 46(5): 938-941.
[51] 张丁元, 石璐瑶, 李燕京. 光动力治疗在肿瘤治疗中的分子机制及临床应用研究进展[J]. 肿瘤学杂志, 2026, 32(1): 69-75.
[52] 李勇, 王强, 张艳. 国单中心PDT/SDT治疗高发肿瘤的临床试验分析[J]. 中国肿瘤临床, 2022, 49(18): 945-951.
[53] 王丽, 陈明, 刘军. 国内PDT/SDT多中心合作研究及生活质量评估[J]. 肿瘤防治研究, 2023, 50(6): 589-596.
[54] 赵刚, 李娜, 张强. 国内PDT/SDT临床试验终点标准化及盲法实施的现状与改进[J]. 中国临床药理学杂志, 2023, 39(11): 1623-1627.
[55] Lingyan Yang, Shan He, Chen Tang, et al. Synthesis of porphyrin-formononetin derivatives and their anti-tumor activity studies[J]. Molecular Diversity, 2026, 30(1): 509-530.
[56] 齐硕, 吴凡, 邱俊, 等. 光动力治疗改善肿瘤微环境和提高肝癌免疫治疗疗效的研究进展[J]. 分子影像学杂志, 2023, 46(5): 938-941.
[57] 李学刚, 冯华, 李飞. 脑胶质瘤光动力治疗及光敏剂引导手术的研究与临床应用进展[J]. 中南大学学报(医学版), 2018, 43(4): 360-367.
文章导航

/

〈 〉